German medical devices maker Biotronik has secured approval from the US Food and Drug Administration (FDA) for the Orsiro drug-eluting stent (DES) system for the treatment of coronary artery disease.

Made of cobalt chromium metal, the Orsiro stent is designed to elute the sirolimus compound through the company’s bioabsorbable polymer coating called BIOlute.

The device is said to feature ultrathin stent struts. It is intended for use in percutaneous coronary intervention (PCI) procedures, and is available in 52 sizes ranging between 2.25mm and 4mm in diameter and lengths up to 40mm.

“The company has said that so far the stent has been used for the treatment of more than one million patients worldwide.”

In the pivotal BIOFLOW-V clinical trial, the Orsiro stent led to significantly lower target lesion failure (TLF) and target vessel myocardial infarction (MI) rates, compared to Abbott’s Xience DES, at 12 months.

Orsiro demonstrated further improvements in event rates at two years, including a significant decrease in target lesion revascularization (TLR) and spontaneous MI, compared to Xience.

Biotronik president Ryan Walters said: “The FDA approval of Orsiro changes the dynamic of what had become a highly commoditized DES market. We designed Orsiro for use even in challenging cases with features that make it unlike any other DES in the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Hospital administrators now have available a DES that shows improved clinical event rates and interventionalists can rely on Orsiro’s deliverability to treat complex lesions and challenging subgroups to achieve unprecedented patient outcomes.”

Orsiro secured the European CE-Mark clearance in 2011. The company has said that so far the stent has been used for the treatment of more than one million patients worldwide.

In September last year, Biotronik received the FDA approval for PK Papyrus Covered Stent in emergency acute coronary perforations treatment.

A balloon-expandable covered coronary stent, PK Papyrus is said to be the first FDA approved device for this indication in 17 years.